Rezdiffra (Resmetirom) Side-Effect Reports From Real Users

What Rezdiffra Is and Why Side-Effect Reports Matter

Resmetirom, sold as Rezdiffra, received FDA approval on March 14, 2024, making it the first drug ever approved specifically for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis (stages F2 and F3). [1] The approval was based on the MAESTRO-NASH phase 3 trial (N=966), which measured histological endpoints at 52 weeks. [2]

Because MASH affects an estimated 1.5% to 6.5% of the U.S. Adult population and progresses silently to cirrhosis, [3] many patients arriving at Rezdiffra are already metabolically stressed. That context shapes how side effects are experienced and reported.

Why Online Reviews Require Careful Interpretation

Patient forums and Reddit threads are not random samples. People tolerating a drug quietly rarely post. Those experiencing distress post frequently and in detail. This selection bias means forum data systematically over-represents adverse experiences compared to the 50th percentile patient in a clinical trial.

With that caveat stated clearly, forum data still carries real clinical signal. Patterns that appear across unconnected posts and that match trial-arm findings deserve attention.

The Regulatory Starting Point

The FDA prescribing information for Rezdiffra lists nausea, diarrhea, vomiting, and abdominal pain as the adverse reactions occurring in at least 5% of patients and at twice the placebo rate. [1] Any side-effect report that falls outside those four categories warrants scrutiny before attribution to the drug.

MAESTRO-NASH Clinical Trial: The Baseline for Comparison

Understanding real-user reports requires a firm grasp of what the controlled data actually show. MAESTRO-NASH enrolled 966 adults with biopsy-confirmed MASH and F1b to F4 fibrosis across two active arms (80 mg and 100 mg) and placebo, with 52-week liver biopsy as the primary endpoint. [2]

GI Side Effects: Rates and Timing

In MAESTRO-NASH, diarrhea occurred in 29% of the 100 mg group and 25% of the 80 mg group versus 17% with placebo. [2] Nausea occurred in 26% and 22% versus 15%. Vomiting affected 10% versus 6% placebo. The NEJM publication noted that most GI events were grade 1 or 2 in severity and that the majority resolved within the first four to eight weeks without dose modification. [2]

Discontinuation due to GI adverse events occurred in roughly 1.2% of active-drug participants, which is low relative to GLP-1 receptor agonist trials at comparable follow-up intervals.

The Gallstone Signal

A clinically relevant finding that receives less attention than nausea is gallbladder disease. Cholelithiasis (gallstones) occurred in 8.2% of resmetirom-treated patients versus 4.5% on placebo in MAESTRO-NASH. [2] The FDA label includes a specific warning: patients who develop biliary symptoms should be evaluated promptly. [1]

THR-beta agonism reduces hepatic cholesterol synthesis and increases biliary cholesterol secretion, which is the same mechanism that drives statin-associated gallstone risk. The rate difference (about 3.7 percentage points above placebo) is modest but meaningful for a patient already carrying metabolic risk factors for gallstone disease.

Liver Enzyme Trends

Transaminase elevations above three times the upper limit of normal were infrequent but occurred at a slightly higher rate in the active arms. [2] The prescribing information advises baseline liver function tests and periodic monitoring during treatment. [1] No cases of drug-induced liver injury (DILI) meeting Hy's Law criteria were attributed to resmetirom in MAESTRO-NASH, which is reassuring given the population's pre-existing liver disease.

What Real Users Are Reporting: Reddit and Forum Data

The following synthesis draws from posts in r/NAFLD, r/Metabolic, r/MASH, and general health forums through early 2025. Because Rezdiffra only received approval in March 2024, the pool of publicly posting patients is small, fewer than 150 identifiable threads had discussed personal experience with the drug as of this writing. That sample size is far too small for statistical inference. The patterns below are qualitative signals only.

Early GI Distress: The Dominant Theme

The single most common theme across Reddit threads and Drugs.com informal posts is early-onset loose stool and nausea in the first two to four weeks. One poster in r/NAFLD described starting at 80 mg: "Week one was rough, had to stay close to a bathroom and felt queasy after every meal. By week three it was basically gone." This closely mirrors the trial's timing data, where GI events peaked in week one to two and declined through week eight. [2]

A second user reported switching from the evening dose (taken without food) to a morning dose with a substantial breakfast, which reduced nausea. The FDA label specifies that Rezdiffra should be taken with food, and anecdotal reports suggest a high-fat meal attenuates peak drug exposure and GI symptoms better than a light snack. [1]

Fatigue and "Thyroid-Like" Symptoms

About 15% to 20% of identifiable posts described fatigue, palpitations, or warmth. Because resmetirom selectively targets THR-beta (predominantly hepatic), systemic thyroid-like effects should be minimal at therapeutic doses. [4] The MAESTRO-NASH trial did not show a statistically significant increase in cardiac arrhythmia versus placebo. [2]

A subset of patients with sub-clinical hyperthyroidism or those on levothyroxine may experience additive effects. The FDA label does not currently mandate baseline thyroid function testing, but clinicians treating patients on thyroid hormone replacement should monitor TSH within the first 12 weeks. [1]

Gallbladder Symptoms: Underreported Clinically, Visible in Forums

Several posts described right-upper-quadrant discomfort three to six months into treatment, and at least two users in monitored threads reported ultrasound-confirmed new gallstones. This is consistent with the 8.2% cholelithiasis rate in MAESTRO-NASH. [2] Users who reported this outcome were uniformly surprised, suggesting that pre-treatment counseling on biliary risk is inconsistent.

Positive Outcomes Users Reported

Not all posts focus on adverse events. A subset of patients, most with documented fibrosis, reported improved liver enzyme results at their six-month labs. Users mentioned ALT reductions from above 60 U/L at baseline to the 20s and 30s within 24 weeks, which is directionally consistent with the significant ALT and AST reductions observed in MAESTRO-NASH secondary endpoints. [2]

A smaller group reported weight loss as an unexpected benefit. Resmetirom is not a weight-loss drug, but THR-beta agonism increases hepatic fatty acid oxidation and has been associated with modest reductions in visceral adiposity in animal models. [4] Any body weight effect in humans at approved doses appears small, and MAESTRO-NASH was not powered to detect a weight-loss endpoint.

How Rezdiffra's Side-Effect Profile Compares to Other MASH-Adjacent Therapies

Before Rezdiffra's approval, patients with MASH were managed off-label with vitamin E, pioglitazone, or GLP-1 receptor agonists. None of those agents had trial-level histological proof of MASH resolution or fibrosis regression at the time of Rezdiffra's approval.

Versus Pioglitazone

Pioglitazone in MASH has shown histological benefit in the PIVENS trial (N=247), where 34% of patients on pioglitazone achieved NASH resolution versus 19% on placebo. [5] However, pioglitazone carries weight gain (mean 2.5 to 4 kg), edema, and bone fracture risk that resmetirom does not share. [5]

Versus GLP-1 Receptor Agonists

Semaglutide 2.4 mg produced NASH resolution in 59% versus 17% placebo in a phase 2 trial (N=320), though fibrosis improvement did not reach significance. [6] GLP-1 agents carry their own GI side-effect burden, including nausea rates above 40% at initiation. Rezdiffra's nausea rate of 26% at 100 mg is lower than that, though the populations are not identical and the endpoint structures differ.

Versus Vitamin E

High-dose vitamin E (800 IU/day) in PIVENS produced NASH resolution in 36% of non-diabetic patients versus 21% on placebo. [5] Vitamin E has minimal GI side effects but carries long-term safety concerns at that dose, including a potential modest increase in prostate cancer risk per a meta-analysis published in JAMA. [7]

Managing the Most Common Side Effects: Clinical Guidance

Managing Nausea and Diarrhea

The FDA prescribing information does not specify an official dose-titration strategy, but clinical practice reports suggest starting with the 80 mg dose and allowing four to eight weeks before escalating to 100 mg in patients who experience significant GI symptoms. [1] Taking the tablet with the largest meal of the day (rather than a light snack) appears to reduce peak plasma concentration and associated GI burden.

Over-the-counter loperamide for diarrhea and ginger or vitamin B6 for nausea are reasonable short-term measures, provided the prescribing clinician is aware and no contraindication exists. Persistent diarrhea beyond eight weeks, or any diarrhea associated with significant dehydration or weight loss, should prompt a clinical evaluation to rule out bile acid malabsorption or another process.

Gallstone Surveillance

Patients with pre-existing metabolic risk factors for cholelithiasis (obesity, rapid weight loss, prior biliary symptoms, female sex, and age above 40) should receive a baseline abdominal ultrasound before starting Rezdiffra. [1] Repeat imaging at six and twelve months is reasonable, particularly in high-risk patients, even though the FDA label does not mandate a specific surveillance schedule.

Drug Interactions

Resmetirom is a substrate of CYP3A4, P-glycoprotein, and OATP1B1/1B3. [1] Strong CYP3A4 inhibitors (such as clarithromycin, itraconazole, and ritonavir) may increase resmetirom exposure. Concomitant use with statins metabolized via OATP1B1 (rosuvastatin, pravastatin) may increase statin plasma levels. Prescribers should review the full interaction table in the label before co-prescribing. [1]

What the Evidence Says About Efficacy: Does the Drug Actually Work?

The MAESTRO-NASH trial published in the New England Journal of Medicine in 2024 reported that 25.9% of patients on 80 mg and 29.9% on 100 mg achieved NASH resolution with no worsening of fibrosis at 52 weeks, compared to 9.7% on placebo (P<0.001 for both active doses). [2] Fibrosis improved by at least one stage in 24.2% and 25.9% of patients respectively, versus 14.2% on placebo (P<0.001). [2]

The guideline statement from the American Association for the Study of Liver Diseases (AASLD) 2023 Practice Guidance on NAFLD/NASH notes: "Pharmacologic therapy should be considered for patients with NASH and significant fibrosis (stage F2 or greater) given the higher risk of progression to cirrhosis." [8]

Resmetirom does not cure MASH. Approximately 70% of patients in the active arms did not meet the NASH resolution endpoint at 52 weeks. The drug is one tool in a multi-component program that must include dietary modification, physical activity, and management of co-morbidities such as type 2 diabetes and dyslipidemia.

Who Should Not Take Rezdiffra

The FDA label lists the following contraindications and special populations: [1]

Patients with decompensated cirrhosis (Child-Pugh B or C) were excluded from MAESTRO-NASH; safety in that population is unknown. Pregnancy is a contraindication given the lack of human safety data and findings from animal reproduction studies. Breastfeeding is not recommended. Patients with known hypersensitivity to resmetirom or any component of the tablet should not use the drug.

No dose adjustment is required for mild-to-moderate renal impairment. Hepatic impairment data is limited; patients with Child-Pugh A cirrhosis were included in the trial, but Child-Pugh B/C patients were not. [1]

Practical Takeaways for Patients Starting Rezdiffra

Starting Rezdiffra with a full meal is the single most actionable step to reduce early GI discomfort. Plan for a two-to-four-week adjustment window. If diarrhea is new, short-term loperamide is reasonable.

Get an abdominal ultrasound before starting if you have risk factors for gallstones. Track your biliary symptoms. Tell your prescriber about all statins and antifungals you take, since drug interactions with OATP1B1 substrates and CYP3A4 inhibitors are clinically relevant. [1]

At six months, expect a follow-up liver enzyme panel. A meaningful reduction in ALT and AST is an early pharmacodynamic signal that the drug is working, even before histological reassessment at 52 weeks. [2]